AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children (ARTEMIS)

Trial Profile

AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children (ARTEMIS)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Acronyms ARTEMIS
  • Sponsors Aimmune Therapeutics
  • Most Recent Events

    • 12 Mar 2018 According to an Aimmune Therapeutics media release, data will be available in 1H 2019.
    • 07 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 14 Feb 2018 According to an Aimmune Therapeutics media release, Prof. George du Toit, M.B., B.Ch., (a Professor of Paediatric Allergy at Kings College London, Guys and St. Thomas NHS Foundation Trust) who is now the member of Scientific Advisory Board of the Aimmune Therapeutics, is a principal investigator for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top